MoonLake beats Q2 2026 EPS estimates with non-GAAP EPS -0.84 and posts positive Phase 3 IZAR-1 psoriatic arthritis results
- Non-GAAP EPS was -0.84 in Q2 2026, improving 3% year-over-year.
- Q2 2026 revenue was $0, beating revenue estimates despite no reported product revenue.
- Positive Phase 3 IZAR-1 results were achieved in biologic-naïve patients with psoriatic arthritis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.